Can a company be convicted for what it bought? A Kentucky firm pleaded guilty on three elements, and not one of them is about anything the company said
Reference page · published 2026-10-29
Disclosure: this index is operated by Artemis Labs, which sells research compounds to laboratories. Artemis Labs buys vials it did not manufacture and ships them to buyers who pay for them. The case on this page is about a company that was convicted for doing those two things with the wrong goods in the middle, so our interest in it is direct and it goes at the top of this page, not buried at the bottom. Nothing here is legal advice. If you run a business that receives anything regulated as a drug, the only correct use of this page is to take it to a lawyer. Nothing on this page tells anybody how to use any compound. Every quotation below is verbatim from a federal court filing, the United States Code, the Code of Federal Regulations, or a United States Attorney's public announcement — each document fetched and read for this page on October 29, 2026, and each listed under Sources. Three documents in this case cannot be quoted at all, including the one that contains the government's own list of the elements. A section near the end explains why, and that limitation shaped what this page can say.
Short answer: yes, and the list of things the government has to prove is shorter than most people expect. For the offense this company pleaded guilty to, the government must show that the company received a drug in interstate commerce, that the drug was misbranded, and that it was delivered for pay or otherwise. That is the whole prohibited act as Congress wrote it. There is no element about knowing the goods were misbranded, no element about intending anything, and no element about a single word the company wrote, said, or published. The first and third parts describe ordinary commerce. Everything turns on the middle one.
What happened
On June 9, 2025, a business in Laurel County, Kentucky called Facial Expressions appeared in the United States District Court for the Eastern District of Kentucky and pleaded guilty to one count. The United States Attorney's office announced it eleven days later:
A Laurel County, Kentucky company, Facial Expressions, pleaded guilty to the receipt of misbranded drugs in interstate commerce.
The business was a clinic that bought drugs derived from botulinum toxins and used them on paying customers to smooth skin wrinkles. According to the announcement, it bought them abroad:
between August 2019 and August 2023, Facial Expressions purchased botulinum toxin type A drugs that were manufactured, packaged, and labeled for sale in Korea and/or Turkey, and thus were not authorized for use inside the United States by the FDA
Two things about that sentence are worth slowing down for, because they are the whole reason this record is on this site.
First, the problem is not that the drugs were fake. Nobody alleged that. The announcement says
they were manufactured, packaged, and labeled for sale in Korea and/or Turkey
— real
products, made for a real market, just not this one. Second, the defendant is a
company. Not an executive, not an owner in her personal capacity. The caption reads
United States of America v. Facial Expressions. Most criminal records in this index punish
a human being for something that human being wrote. This one punishes a business for what it bought.
The prohibited act, in one sentence
The federal food and drug law lists the things it forbids. The one charged here is paragraph (c), and it is short enough to read in a breath:
The receipt in interstate commerce of any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise.
Read it looking for a state of mind. There is none. No knowingly. No willfully. No with intent to. The sentence describes two physical events — a receipt and a delivery — with a condition on the goods in between.
Break it into its parts and you have the structure of the offense:
- Receipt — the goods came to you, across a state or national line.
- The goods were misbranded — this is the condition, and it is about the article, not about you.
- Delivery for pay or otherwise — you passed them on. Note
or otherwise
: getting paid is not required. Handing them over is enough.
A business that buys inventory and ships it to customers performs the first and third of those every working day. That is not a loophole or an edge case; it is a description of retail and wholesale distribution. The entire question is whether the thing in the middle was a misbranded drug.
What it costs, and the trap in the second paragraph
The penalty provision has two tiers. The first is the misdemeanor:
Any person who violates a provision of section 331 of this title shall be imprisoned for not more than one year or fined not more than $1,000, or both.
That is the tier this company pleaded to. The second tier is the felony, and it has two separate doors into it:
commits such a violation with the intent to defraud or mislead, such person shall be imprisoned for not more than three years or fined not more than $10,000, or both
Intent to defraud is one door. The other, in the same sentence, is having a prior conviction under this Act that has become final. So a first misdemeanor conviction — the kind that costs a modest fine and no prison — quietly changes the exposure on everything that comes after it. We cover that mechanism separately in what turns a misbranding charge into a felony.
The dollar figures in the statute are not what a defendant actually pays. Federal fine levels
are set elsewhere, and the public announcement of the related individual case gives a sense of the
real range: it said the owner, in her own separate matter, faces up to four years in prison and
a maximum fine of $250,000.
That is a different case against a different defendant, and we note
it only so the $1,000 in the statute is not mistaken for the ceiling.
The two ways the goods were misbranded, and both are about marks on a label
The word misbranded sounds like it should mean a lie. In this Act it does not have to. It is a defined status, and a drug can fall into it without anyone saying anything false.
Two definitions were in play here. The first requires directions:
Unless its labeling bears (1) adequate directions for use
A drug whose labeling does not carry adequate directions for use is misbranded. The regulation defines what adequate means, and the standard is set by who has to follow the directions:
Adequate directions for use means directions under which the layman can use a drug safely and for the purposes for which it is intended.
A layman. Not a pharmacist, not a physician — an ordinary person with no training. Hold that thought, because it is the hinge of the whole argument.
The second definition is about a symbol:
A drug that is subject to paragraph (1) shall be deemed to be misbranded if at any time prior to dispensing the label of the drug fails to bear, at a minimum, the symbol “Rx only”.
A prescription drug whose label does not say Rx only
is misbranded. That is it. No claim,
no advertisement, no statement to a customer. A missing mark on a label.
The same provision runs the other way, and almost nobody mentions it
The very next subparagraph is the mirror image, and it deserves to be read by anybody who labels anything:
A drug to which paragraph (1) does not apply shall be deemed to be misbranded if at any time prior to dispensing the label of the drug bears the symbol described in subparagraph (A).
In plain language: if a drug is a prescription drug, leaving Rx only
off
makes it misbranded. If a drug is not a prescription drug, putting Rx only
on makes it misbranded. The symbol is not decoration and it is not a cautious extra. It is
a status marker, and using it wrongly in either direction is the defined offense.
This cuts against a habit that is common in our own market, where sellers sometimes add official-looking marks to a label because the marks look serious. Under this provision, a mark that claims a status the article does not have is not caution. It is the violation.
The loop that makes the result automatic, and both sides agreed to it out loud
Here is the part of this record that is genuinely unusual, and it exists only because of something that went slightly wrong in the paperwork.
When a defendant pleads guilty, the court has to satisfy itself there is a factual basis for the plea. Normally the plea agreement spells out the theory. Here it did not, so the magistrate judge had to establish it on the record. His written recommendation says so:
The Court questioned Defendant in detail concerning the factual basis, in particular ensuring that, although not specified in the plea agreement, the products at issue were misbranded as alleged in paragraph 24 of the information, meaning they lacked adequate directions for use (without a statutory exemption) and did not bear the symbol “Rx.”
And then, in the same paragraph, the court recorded a formula that the prosecution and the defense both signed off on:
both counsel agreed that “A drug is misbranded if it is a prescription drug that is an unapproved new drug, because a prescription drug cannot bear the adequate directions for use required by statute [18 U.S.C. § 352(f)(1)] and the lack of an approved NDA means that there is no FDA exemption from the adequate directions for use requirement.
Walk that in slow steps, because it is a closed circle:
- A prescription drug, by definition, is one that cannot be used safely without a practitioner supervising. So it cannot carry directions a layman could follow safely. The adequate-directions requirement is therefore impossible for it to meet.
- There is an exemption from that requirement — otherwise every prescription drug in the country would be misbranded.
- But the exemption is conditioned on having an approved application.
- So if the drug is a prescription drug and has no approved application, the requirement cannot be met and the exemption is not available. Misbranded, with nothing left to argue.
Notice what is absent from every step. No claim. No advertisement. No statement to a customer. No test result. No intent. Once the article is characterized as an unapproved prescription drug, the misbranding follows from the characterization itself.
The court cited one case for the proposition, and it is the only judicial authority named anywhere in the set of filings we read: United States v. An Article of Drug . . . “Mykocert,” 345 F. Supp. 571, 573 (N.D. Ill. 1972).
The exemption is about who is holding it, not only what the label says
The formula above leans on the exemption without quoting it. We fetched it, and it contains something the formula does not make obvious. The regulation opens like this:
A drug subject to the requirements of section 503(b)(1) of the act shall be exempt from section 502(f)(1) if all the following conditions are met
All the following conditions. The first one is not about the label at all. It is about whose hands the drug is in:
In the possession of a person (or his agents or employees) regularly and lawfully engaged in the manufacture, transportation, storage, or wholesale distribution of prescription drugs
— or a pharmacy, or a public health agency, or:
In the possession of a practitioner licensed by law to administer or prescribe such drugs
And a later condition closes the other end:
the labeling bearing such information is the labeling authorized by the approved new drug application
So the exemption that saves every lawfully distributed prescription drug in America from being misbranded has two kinds of condition bolted together: a condition about the holder and a condition about the approved labeling. A party outside that list of holders does not get the exemption even with a perfect label. A party inside the list does not get it for an article with no approved application. This is the step the agreed formula compresses into one clause, and it is worth seeing in full, because it explains why the status of the buyer matters as much as the condition of the package.
How fast it closed
The procedural history is short, and the speed is part of the story.
The magistrate judge took the plea on June 9, 2025, found the company competent to plead and the
plea knowing and voluntary, and recorded that he had found that an adequate factual basis
supporting the plea as to each essential offense element for the applicable charge was presented.
He then recommended the outcome:
the Court RECOMMENDS that the presiding District Judge ACCEPT the guilty plea of FACIAL EXPRESSIONS and ADJUDGE it guilty of the Information.
He gave the parties an unusually short window to object —
within THREE days after being served with a copy of this decision, a party may serve and file
specific written objections
— citing the need for prompt disposition and the Speedy Trial
Act.
Nobody objected. The district judge's order, dated June 20, 2025, says so in one line:
The established three-day objection deadline has passed, and no party has objected.
And that silence had a legal consequence the order spells out, quoting the Supreme Court:
The Court is not required to “review . . . a magistrate[ judge]’s factual or legal conclusions, under a de novo or any other standard, when neither party objects to those findings.
Then the conviction:
The Court ADOPTS DE 13, ACCEPTS Defendant’s guilty plea, and ADJUDGES Defendant guilty of the Information
From the plea hearing to an adjudication of guilt: eleven days.
The money, and the part of it that was decided before sentencing
The same order dealt with forfeiture, and it is worth noting that this happened on a misdemeanor:
the Court provisionally FINDS that the property identified in the Information’s Forfeiture Allegations, see DE 8 at 7 (the money judgment of $10,911), is forfeitable
Ten thousand nine hundred and eleven dollars, described as the proceeds of the violation. The
order explains the timing: under the criminal rules, and absent an objection before judgment,
the preliminary forfeiture order becomes final as to
the defendant at sentencing. So the
forfeiture was effectively settled at the plea stage, months before any sentence was imposed.
Separately, the public announcement describes harm to customers and a figure attached to it:
Multiple customers experienced side effects linked to the botulinum injections that they received at Facial Expressions during this period.
In total, these customers incurred additional medical expenses of at least $24,369 to fix these side effects.
Two cautions on those two sentences, and we are flagging both without resolving either.
The phrase linked to
is not a finding of cause, and a prosecutor's public announcement is
not a judicial finding of anything. The document where a court would record what it actually found about harm is
the judgment — and as the next section explains, we could not read it. Also note the
direction of the arithmetic: the money the company is recorded as having taken in,
$10,911, is smaller than the customers' recorded additional medical costs,
$24,369. We state both figures and draw no conclusion from the gap.
What this page cannot tell you: the sentence
We do not know what punishment this company received, and we want to be precise about why, because "unknown" and "unobtainable" are different claims.
The judgment exists. It is document 24 on the docket, it is held in the public court-records archive, and we downloaded it successfully on October 29, 2026. It is five pages and 163,847 bytes. It is also a photograph of a piece of paper. When we extracted its text layer, the entire five-page document yielded not one readable character — the only output was the blank page separators our own extractor inserts between pages. There is nothing in it a machine can read.
We checked two other routes before giving up on the figure:
- A public sentencing announcement. We queried the Justice Department's press release index for every release whose title contains misbranded, newest first, and read 50 of them spanning April 2023 to September 2026. The June 20, 2025 plea announcement is in that set — which proves the search reaches this case — and it is the only one of the 50 that names Facial Expressions anywhere in its title or body. Twelve releases in the set are newer than it, and none concerns this company. A nonsense control term returned nothing, so the search is discriminating, not matching everything in sight.
- The docket's own summary text. Nothing in what is publicly readable states the imposed sentence.
So the honest statement is this: the company was convicted, and we cannot tell you what it was sentenced to. The statutory ceiling for this tier is quoted above. What the court actually imposed is recorded on a page nobody can read without paying for it. Anyone who tells you the outcome of this case, in either direction, is working from something other than these documents.
Three documents in this case cannot be quoted at all, including the one with the elements
This section is about our own method, and it is here because it changed what this page says.
Five documents from this docket are publicly available at no cost. Before reading any of them, we classified each one's text layer from its raw bytes, which is the only reliable way to tell a document that was typed from a document that was photographed and then machine-read. The result:
- The Recommendation (3 pages) — genuine text. Quotable. Quoted above.
- The Order adopting it (2 pages) — genuine text. Quotable. Quoted above.
- The Information, the charging document (9 pages) — a scan.
- The Plea Agreement (7 pages) — a scan.
- The Judgment (5 pages) — a scan with effectively no text at all.
For the two middle ones, the machine-read text is readable enough to tempt you and wrong in
exactly the places that matter. The strings below are not quotations of those documents —
they are specimens of what the machine produced when it tried to read them, which is a different
thing and is why they are set in a different typeface. In the recovered text of the charging
document, the statute 331 comes out as 33l(, with a lowercase letter L
standing in for the digit 1; the subsection 352(f)(1) comes out as
352(f)(l), same substitution; the word property comes out as
prope1iy. In the plea agreement, misdemeanor comes out as
misderneanor, Information becomes Infbnnation, and a statutory
citation collapses into rs l5l.
That last one matters more than the comic ones. The plea agreement is the document that contains the government's own numbered list of the elements of this offense — the single most useful paragraph in the whole file, and the reason we chose this case. A machine's transcription of it is not a quotation of it. A person can guess what the mangled citation was meant to be, and the guess is probably right, but a guess printed inside quotation marks is a different kind of statement than a quotation, and we will not make it.
So the elements as described at the top of this page are drawn from the statute
itself, which we fetched from the United States Code and quoted verbatim, and from the
magistrate judge's native-text recommendation, which confirms that the court found a factual basis
as to each essential offense element for the applicable charge was presented.
We have not put
the government's own wording of the
elements on this page, because we cannot read it. That is a smaller page than the one we set out to
write, and it is the correct one.
Our general method for this, including how to tell a scanned filing from a typed one, is on can you search a court filing.
Two defects in the record itself, reported and not tidied up
A citation error, in a judicial recommendation that a district judge adopted.
The agreed formula quoted above cites [18 U.S.C. § 352(f)(1)]
. The adequate-directions
requirement is in Title 21, not Title 18. The surrounding sentence is unambiguously
about the food and drug law, nothing turns on it, and we would not mention it except that it is a
typing slip in the highest-authority document we read — and it was adopted without objection
by a district judge. This is not the first citation defect we have found in an official record and
it will not be the last. A citation field is a drafter's work at every institution, including the
federal bench.
A form built for a human being, applied to a company. The recommendation puts
the corporate defendant through the standard colloquy script, and the script's pronouns show. It
records informing the defendant of his/her right to rearraignment
, and it closes by noting
that the district judge will, as necessary, address Defendant’s custodial status when
considering this Recommendation.
A company has no custodial status. The boilerplate is harmless
here, but it is a small, honest piece of evidence about how rarely the corporate version of this
proceeding comes up.
What does the evidence not show?
This is the section most pages like this one leave out. The documents we read have real limits and several of them cut against the reading above.
- The sentence is unknown. Covered at length above. Any claim about what this conviction actually cost, including a claim that it cost little, is not supported by anything we read.
- We never read the government's elements paragraph. The three-part structure described on this page is read off the statute, which is the authority the elements must follow — but the government's own numbered version is in a document we graded unquotable, and we did not substitute a reconstruction for it.
- This was a guilty plea, not a trial. Nothing here was tested by cross-examination or decided by a jury. A defendant who pleads guilty has reasons for pleading that the file does not record, and those reasons are frequently about cost and time, not about the merits. The agreed formula in the recommendation is agreed; it is not a holding.
- The agreed formula was not litigated. Because both counsel accepted it, no judge was ever asked whether it is right. It appears in a recommendation, not an opinion, and the order adopting it expressly says the district judge was not required to review the magistrate judge's legal conclusions because nobody objected. That means the most quotable sentence on this page carries less precedential weight than its tone suggests, and we would rather say so than let the quotation marks do work the document cannot support.
- The harm figure is not a judicial finding. The
at least $24,369
and theside effects linked to
phrasing come from a prosecutor's public announcement, written to be read by the public. A court's own characterization of harm would be in the judgment, which is unreadable. - The compounds here are not research peptides. This case is about botulinum toxin products bought by a clinic that used them on people. The mechanism — receipt, plus a misbranded article, plus delivery for pay — does not care what the article is, which is why the record is relevant. But nothing in this file is a ruling about research compounds, and we are not going to pretend the facts are closer to ours than they are.
- A separate case about a person is not this case. The public announcement describes a guilty plea by the company's owner to giving false information to the Drug Enforcement Administration on a registration renewal. That is a different defendant, a different statute, and a different docket. The sentencing exposure quoted in that announcement belongs to that matter, not to this one. We mention it only because the two are announced together and are easy to merge by accident.
Where we stand on this
We said at the top that our interest here is direct, so here is the specific thing we take from this record, stated as plainly as we can.
The first and third elements of this offense describe what Artemis Labs does as a matter of routine: it receives goods it did not make, and it delivers them to people who pay. There is no version of this business that avoids those two elements, and there is no point pretending otherwise. Nor is the middle element something we could fix by writing better copy, because none of the three has anything to do with what a seller writes. Every other enforcement mechanism in this index — intended use read off a product page, a benefit claim, a disclaimer read as evidence — can in principle be managed by being careful with language. This one cannot. It turns entirely on how the article itself is characterized in law.
That is why this page exists, and it is also where the page stops. Whether any particular
article is a prescription drug
within the meaning of the provision quoted above is a legal
question about a specific product, with a specific regulatory history, and it is a question for a
lawyer looking at that product. It is not a question a vendor should be answering on its own
website, including this one. We have set out the mechanism and the documents; we have deliberately
not applied them to our own catalog in public.
The one practical observation we will make is the one in the symmetry section above, because it is general, not product-specific, and it points the opposite way from most compliance instincts: adding an official-looking status mark to a label is not a safe default. Under the provision quoted, a status mark on an article that does not have that status is itself a defined misbranding. Caution that takes the form of adding regulatory-looking marks can create the violation it was meant to avoid.
Sources
Every document below was fetched and read on October 29, 2026. Court filings came from the public court-records archive at no cost; a deliberately invalid document number on the same docket returned a 404, which is how we know a successful download means the document genuinely exists and not the server answering yes to everything. Each PDF's text layer was classified from its raw bytes before anything was quoted from it, and the three documents graded as scans are quoted nowhere on this page.
- Recommendation of Acceptance of Guilty Plea, United States v. Facial Expressions, No. 6:25-cr-00047-REW-HAI (E.D. Ky.), document 13, filed June 10, 2025, 3 pages. Magistrate Judge Hanly A. Ingram. Text layer verified as genuine text before quoting. storage.courtlistener.com (document 13)
- Order adopting the Recommendation, same case, document 14, filed June 20, 2025, 2 pages. District Judge Robert Earl Wier. Text layer verified as genuine text before quoting. storage.courtlistener.com (document 14)
- Information, same case, document 8, 9 pages. Classified as a scan and quoted nowhere on this page. Fetched only to grade it. storage.courtlistener.com (document 8)
- Plea Agreement, same case, document 9, 7 pages. Classified as a scan and quoted nowhere on this page, including its elements paragraph. storage.courtlistener.com (document 9)
- Judgment, same case, document 24, 5 pages, 163,847 bytes. A scan yielding no readable text at all across five pages. Not read, and the reason the sentence is not stated on this page. storage.courtlistener.com (document 24)
- U.S. Attorney's Office, Eastern District of Kentucky, Laurel County Company Pleads Guilty to Obtaining Misbranded Injectable Drugs, June 20, 2025. Retrieved through the Justice Department's press-release index, because the page itself is served behind a bot-protection challenge that returns no readable body. justice.gov
- 21 U.S.C. § 331 — Prohibited acts. Subsection (c) quoted above. govinfo.gov
- 21 U.S.C. § 333 — Penalties. Subsections (a)(1) and (a)(2) quoted above. govinfo.gov
- 21 U.S.C. § 352 — Misbranded drugs and devices. Subsection (f) quoted above. govinfo.gov
- 21 U.S.C. § 353 — Exemptions and consideration for certain drugs. Subsections (b)(4)(A) and (b)(4)(B) quoted above. govinfo.gov
- 21 CFR 201.5 — Drugs; adequate directions for use. Quoted above. ecfr.gov
- 21 CFR 201.100 — Prescription drugs for human use. Subsections (a) and (c) quoted above. Note that the citation path redirects: the section sits in subpart D of part 201, not subpart C. ecfr.gov
- United States v. An Article of Drug . . . “Mykocert”, 345 F. Supp. 571, 573 (N.D. Ill. 1972). Cited in the Recommendation as the authority for the unapproved-to-misbranded formula. We report the citation as the court gave it; we did not separately fetch the opinion, so nothing from it is quoted here.
Related records in this index
- Can you be convicted for a label you did not write? — the same prohibition, applied to individual people instead of a company, and the defense the statute itself provides.
- Can you be convicted for what an employee did? — the route that reaches a named officer personally, with no proof of knowledge.
- Can a court shut a company down? — what a sentencing court can and cannot do to a business.
- The label that names no one — a third misbranding limb, charged on its own in a 2026 indictment: a label that omits who made the product.
- What turns a misbranding charge into a felony? — the second door into the three-year tier, which needs no intent.
- Why do most of these cases end in probation? — what convictions under this Act have actually cost.
- Can the government take the house? — forfeiture at a larger scale than the money judgment here.
- Does moving a drug to somebody who is not a
patient need a license? — the licensing question behind the phrase
authorized and licensed distributor
. - What FDA asks a distributor to do — the civil side of the same receipt-and-delivery conduct.
- Can you search a court filing? — the method behind this page, including why three of its five documents could not be quoted.
- Research-peptide enforcement in 2026 — where this year's records sit.
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.